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Diarrheal diseases are among the leading causes of morbidity and mortality in the world,
particularly among young children. A limited number of infectious agents account for
most of these illnesses, raising the hope that advances in the treatment and prevention
of these infections can have global health impact. The two most important parasitic
causes of diarrheal disease are Cryptosporidium and Giardia. Both parasites infect
predominantly the small intestine and colonize the lumen and epithelial surface, but
do not invade deeper mucosal layers. This review discusses the therapeutic challenges,
current treatment options, and drug development efforts against cryptosporidiosis and
giardiasis. The goals of drug development against Cryptosporidium and Giardia are
different. For Cryptosporidium, only one moderately effective drug (nitazoxanide) is
available, so novel classes of more effective drugs are a high priority. Furthermore, new
genetic technology to identify potential drug targets and better assays for functional
evaluation of these targets throughout the parasite life cycle are needed for advancing
anticryptosporidial drug design. By comparison, for Giardia, several classes of drugs
with good efficacy exist, but dosing regimens are suboptimal and emerging resistance
begins to threaten clinical utility. Consequently, improvements in potency and dosing,
and the ability to overcome existing and prevent new forms of drug resistance are
priorities in antigiardial drug development. Current work on new drugs against both
infections has revealed promising strategies and new drug leads. However, the primary
challenge for further drug development is the underlying economics, as both parasitic
infections are considered Neglected Diseases with low funding priority and limited
commercial interest. If a new urgency in medical progress against these infections can
be raised at national funding agencies or philanthropic organizations, meaningful and
timely progress is possible in treating and possibly preventing cryptosporidiosis and
giardiasis.
Keywords: diarrhea, neglected diseases, protozoan parasites, cryptosporidiosis, giardiasis, antimicrobial drugs,
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The two most frequent parasitic causes of diarrheal disease worldwide are Cryptosporidium and
Giardia. Other parasites, such as Entamoeba histolytica, which is highly invasive and causes amebic
colitis (as discussed in other chapters of this volume), and the coccidia, Cystoisospora belli, and
Cyclospora cayetanensis, have clinical relevance but are less common causes of diarrheal illness. For
instance, the two coccidian parasites are mostly associated with chronic diarrhea in HIV-positive
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individuals (Dash et al., 2013; Mathur et al., 2013) and other
forms of immunodeﬁciency, but are less important causes of
diarrhea in immunocompetent individuals. This review focuses
on the therapeutic challenges, current treatment options, and
ongoing drug development eﬀorts against cryptosporidiosis and
giardiasis.
Cryptosporidium
Cryptosporidium is a major cause of diarrheal disease in humans
and animals. It became clinically ﬁrst known as a causative
agent of profuse and persistent diarrhea and morbidity in
immunocompromised patients, particularly those with acquired
immunodeﬁciency syndrome, and as a major cause of waterborne
diarrheal disease in outbreaks in otherwise healthy individuals.
More recently, large population studies have shown that
Cryptosporidium is among the ﬁve leading causes of diarrheal
disease in young children worldwide (Checkley et al., 2015),
underlining the urgency of addressing the medical needs posed
by this parasite, particularly since current treatment options are
severely limited.
Parasite
Cryptosporidium belongs to the phylum of apicomplexan
protists, along with Plasmodium and Toxoplasma, although
it displays signiﬁcant diﬀerences to those parasites. Most
notably, it has lost the phylum-deﬁning apicomplexan plastid
and lacks mitochondria. Genome comparisons suggest that
Cryptosporidium is more closely related to gregarines, intestinal
protozoa of invertebrates (Carreno et al., 1999; Ryan and Hijjawi,
2015). The parasite is an obligate endosymbiont, depending
on invasion of host cells for numerous metabolic functions.
Consistent with the exploitation of this metabolically rich
biological niche, it has a relatively small eukaryotic genome
of ∼9 Mb with ∼4,000 genes (Abrahamsen et al., 2004; Xu
et al., 2004). Cryptosporidium represents a species complex
comprising at least 27 individual species and over 40 genotypes
with varying degrees of host speciﬁcity (Ryan and Hijjawi, 2015).
Humans can be infected by nearly 20 of these species, but
only two, Cryptosporidium hominis and C. parvum, cause the
majority of clinically relevant infections. C. hominis is limited to
humans, so the infectious cycle is strictly anthroponotic, while
C. parvum has several subtypes of which some are human-
speciﬁc and others have a broader host range and zoonotic
transmission. Importantly, new drugs must be active against
C. parvum and C. hominis as both species have worldwide
distribution.
The entire Cryptosporidium life cycle occurs in a single host
(monoxenous) and involves both asexual multiplication and
sexual reproduction (Laurent et al., 1999) (Figure 1). Infectious
oocysts are ingested by the host, and sporozoites emerge from
the oocysts upon exposure to acidic conditions followed by
neutralization and exposure to pancreatic enzymes and bile
(Smith et al., 2005). Sporozoites attach to intestinal epithelial
cells, are enveloped by the host cell apical cell membrane, and
diﬀerentiate into spherical trophozoites, which occupy a location
that is commonly described as intracellular but extracytoplasmic
(Smith et al., 2005). The parasites reside in a parasitophorous
vacuole, which contains membrane components from the host
and parasite, and allows acquisition of nutrients from the host
cell (Tzipori and Griﬃths, 1998). Importantly, the parasite is
completely covered by host cell membrane during its epithelial
growth phase, so drugs have to cross this membrane to be
eﬀective at that stage of the growth cycle.
During maturation of the Cryptosporidium trophozoite,
asexual multiplication occurs and results in the formation of a
type I schizont that contains six to eight merozoites. Rupture
of the schizont results in the release of merozoites that, in
turn, can invade adjacent host epithelial cells, where they
develop subsequently into type I schizonts, leading to further
rounds of asexual multiplication, or into type II schizonts,
which initiate sexual reproduction by diﬀerentiating into male
microgamonts or female macrogamonts (Current and Reese,
1986). Male microgamonts release microgametes that can
fertilize the macrogametes inside the female macrogamont. After
fertilization, two types of oocysts form, thin-walled oocysts,
which are important in reinfection of the host and expansion
of parasite numbers, and thick-walled oocysts, which exit the
intestinal tract and are infectious for new hosts.
Pathogenesis and Disease
Transmission occurs by the fecal–oral spread of oocysts. In
particular, fecal contamination of drinking water can serve as
a vehicle for transmission of oocysts and is a substantial public
health concern. Large-scale outbreaks have been associated with
contamination of community drinking water (Widerstrom et al.,
2014; Painter et al., 2015). Cryptosporidium invades and resides
for major parts of its life cycles within epithelial cells, most
commonly in the small intestine. The parasite can be viewed
as a “minimally invasive” mucosal pathogen, because it does
not usually penetrate into the deeper mucosal layers. This
restricted epithelial localization has potential implications for
drug design, as it raises the possibility that orally administered
drugs might be eﬀective locally in the intestine without extensive
systemic absorption. Under conditions of immunodeﬁciency,
Cryptosporidium infection can be more widespread and involve
epithelial cells of the biliary tract, pancreatic duct, stomach,
esophagus, and even respiratory tract (Chen et al., 2002).
Under these conditions, systemic drug absorption is probably
required, as a drug with limited intestinal activity would be
unlikely to reach these other mucosal sites (Abubakar et al.,
2007).
Clinical manifestations of Cryptosporidium infection, which
occur after an incubation period of 2–14 days, include watery
and often profuse diarrhea, as well as abdominal cramps,
nausea, vomiting, weight loss, and a low-grade fever (Chen
et al., 2002). In immunocompetent individuals, disease is
usually self-limited lasting 1–3 weeks, whereas the illness is
typically prolonged in immunocompromised hosts. In addition,
in severe infections, malabsorption can be present due to
decreased absorptive surface, which can contribute to the wasting
syndrome in infected AIDS patients (Hunter and Nichols, 2002).
Immunocompromised patients with bile duct infection may also
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FIGURE 1 | Life cycle of Cryptosporidium. Infection is initiated by ingestion of thick-walled and environmentally resistant oocysts that give rise to sporozoites in
the lumen of the small intestine. These invade epithelial cells to form trophozoites in the apical domain of the cells. Growth occurs by asexual multiplication, leading
to further cycles of infection and growth, or sexual multiplication involving gamonts and gametes, and leading to fertilized zygotes. These can differentiate into
thin-walled oocysts that can initiate further rounds of autoinfection, or to thick-walled oocysts that are shed in the feces.
present with jaundice secondary to biliary tract obstruction or
with symptoms of pancreatitis. Furthermore, in young children,
particularly if malnourished, the infectious diarrhea can be
extensive and associated with signiﬁcant mortality (Hunter and
Nichols, 2002). In fact, cryptosporidiosis has recently been
identiﬁed as the second leading cause (after rotavirus) of
diarrheal disease in children <5 years in developing countries
(Kotloﬀ et al., 2013; Liu et al., 2014). With increasing use
of the highly eﬀective rotavirus vaccine it can be expected
that Cryptosporidium will soon become the most important
worldwide cause of childhood diarrhea.
Several mechanisms are thought to contribute to the
pathogenesis of Cryptosporidium-induced diarrhea. In patients
having large volume diarrhea, a secretory process appears to be
important. An enterotoxic activity released by the parasite has
been described (Guarino et al., 1995), but these ﬁndings remain
controversial. In animal models of C. parvum infection, glucose-
stimulated sodium absorption was inhibited and this paralleled
the extent of villous and epithelial cell damage (Kapel et al.,
1997). In addition, increased mucosal prostaglandin production
(e.g., PGE2 and PGI2), which can inhibit neutral NaCl absorption
and result in secretory diarrhea, has been demonstrated in the
porcine model (Argenzio et al., 1990). Such eﬀects may be due,
in part, to PGI2 acting on components of the enteric nervous
system (i.e., cholinergic and VIPergic neuronal pathways), and a
direct action of PGE2 on enterocytes (Argenzio et al., 1993, 1996).
The mechanisms that lead to increased prostaglandin production
and the cellular source of the prostaglandins are not known,
although the latter may include mesenchymal and/or epithelial
cells (Laurent et al., 1998). In addition, resident and recruited
leukocytes in the mucosa (e.g., macrophages) have the potential
to produce high levels of prostaglandins, and may also be a
source of prostaglandin production during C. parvum infection.
Alterations in intestinal permeability may also play a role in
the diarrhea in C. parvum-infected individuals (Zhang et al.,
2000).
Current Treatment Options
Current therapeutic options for cryptosporidiosis are limited and
only one drug, nitazoxanide, has been approved by the Food and
Drug Administration (FDA). Eﬃcacy is variable, with resolution
of diarrheal symptoms and parasitological cure in 50–90% of
HIV-negative children and adults (Rossignol et al., 1998, 2001;
Amadi et al., 2002; Hussien et al., 2013). Typical oral doses are
500-mg twice daily for adults and adolescents, 200-mg doses
twice daily for children aged 4–11 years, and 100-mg doses twice
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daily for children aged 1–3 years, with treatment duration of 3–
14 days. The drug is generally well tolerated. Notably, placebo
treatment resulted in symptom improvements in a signiﬁcant
fraction (30–40%) of patients (Rossignol et al., 2001; Amadi
et al., 2002), underlining that the infection is usually self-limited
in immunocompetent patients. In contrast, nitazoxanide is not
eﬀective in HIV-infected children (Amadi et al., 2002), and is not
FDA approved for this indication.
Other pharmacological interventions have been used clinically
against Cryptosporidium, but they are not FDA-approved for
treating cryptosporidiosis and their eﬃcacy is generally lower
than nitazoxanide. For example, paromomycin (500 mg oral,
four times daily for 2–3 weeks) led to symptom cessation
and microbiological cure in 60–70% of immunocompetent
patients (Vandenberg et al., 2012; Hussien et al., 2013). Results
in HIV-infected adults have been variable, with some studies
showing similar (60–70%) eﬃcacy of paromomycin (Bissuel
et al., 1994; Blanshard et al., 1997), while others reporting
no eﬀectiveness (Hewitt et al., 2000). Immunotherapy has
shown some promise. Most notably, restoration of immune
competence in immunocompromised hosts, particularly an
increase toward normal in the CD4 T cell levels in patients with
AIDS, is associated with clearance of Cryptosporidium (Flanigan
et al., 1992). Passive immunotherapy by oral administration of
colostrum-derived bovine immunoglobulins (which presumably
contained anti-cryptosporidial antibodies as cows get commonly
infected with Cryptosporidium) led to signiﬁcant improvement
of diarrheal symptoms, although microbiological cure was not
evaluated (Greenberg and Cello, 1996). However, nitazoxanide
remains the most eﬀective current therapeutic agent available
against cryptosporidiosis in immunocompetent individuals,
while no consistently eﬀective drugs exist against infection under
conditions of immunodeﬁciency.
Assays for Drug Development
Antimicrobial drug development depends on suitable assays
that recapitulate critical growth phases of the microbe in the
host. This is not usually a problem for growth autonomous
microorganisms, such as most bacterial pathogens, but can be
a challenge for symbionts such as Cryptosporidium that rely
partially or completely on host cells for growth and survival.
Nonetheless, an array of cell culture and animal models is
available for drug testing against the parasite.
Asexual and sexual development of Cryptosporidium can be
achieved in vitro using several diﬀerent cell lines, although the
life cycle is incomplete and the number of oocysts produced
is generally low. A widely used model is the human ileocecal
adenocarcinoma cell line, HCT-8 (Upton et al., 1994; Alcantara
Warren et al., 2008). Monolayers of the cells can be readily
infected in culture (Figure 2), and infection can be optimized
by adding nutritional supplements to the culture media (Upton
et al., 1995). Other mammalian cell lines (e.g., MDCK and Vero)
are also infectable, although parasite development tends to be
less robust than in HCT-8 cells (Upton et al., 1994). Several
of the epithelial cell lines, including human T84 and Caco-
2 cells, can be grown as diﬀerentiated polarized monolayers
on microporous ﬁlter supports, which permits studies of the
FIGURE 2 | In vitro drug assay for Cryptosporidium. HCT-8 human
intestinal epithelial cells were grown as monolayers in 96-well plates to
60–80% confluence. Cryptosporidium parvum oocysts, pretreated for 10 min
at 37◦C with 10 mM HCl and 10 min at 15◦C with 200 μM sodium
taurocholate to promote excystation, were added to the wells (105
oocysts/well). After a 4 h infection period, monolayers were washed, serial
dilutions of nitazoxanide were added, and cultures were incubated for 48 h at
37◦C in 5% CO2 and 95% air. Cells were fixed with 3% formaldehyde,
permeabilized with Triton X-100, and stained with FITC-conjugated Vicia
villosa lectin to detect C. parvum and counterstained with Hoechst 33342 to
detect nuclei. A representative image of host cell nuclei (blue) and parasites
(green) is shown in (A) for controls (left) and after exposure to 20 μM
nitazoxanide (right). A concentration-response curve is shown in (B). Data are
mean ± SD of triplicate wells, and are expressed relative to the parasite load
in untreated controls. The half-maximal inhibitory concentration (IC50) for
nitazoxanide was 0.7 μM.
eﬀects of Cryptosporidium infection on barrier functions, ion
absorption and secretion, and cytokine responses (Griﬃths et al.,
1994; Laurent et al., 1997, 1998). A recent report has also
used primary human intestinal epithelial cells, grown as self-
sustaining organoids (enteroids), for in vitro infections with
Cryptosporidium (Castellanos-Gonzalez et al., 2013a). These
cultures, unlike epithelial cell lines, display the normal range
of intestinal epithelial cell diﬀerentiation, which should allow
more complete analysis of parasite–host interactions than
possible in transformed cell lines, although establishment and
maintenance of primary cultures are technically demanding
at this time and may not yet be readily adaptable to high-
throughput screens. Overall, epithelial cell cultures are poised
to remain an indispensable tool for new drug development
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against Cryptosporidium. It must be borne in mind, however,
that current culture systems probably do not capture all stages
of the cryptosporidial life cycle with equal eﬃciency and
physiological impact, so drug screening eﬀorts may be skewed
toward compounds that are particularly active in the intracellular
life cycle stages, but not any extracellular stages (Hijjawi et al.,
2002).
Antimicrobial activity in vitro is usually necessary for a new
drug candidate, but it is not suﬃcient since many candidates
that work in vitro fail to be active in vivo. Appropriate animal
models are therefore critical for drug development. A number
of mammals have been used for Cryptosporidium infections,
including small (mice, rats) and large animals (pigs, cows),
each with advantages and disadvantages. Most animal models
reproduce the cryptosporidial growth cycle and lead to sustained
infection and shedding of infectious oocysts, which is adequate
for drug eﬃcacy studies. Small animal models, particularly
mice, are resource-eﬀective, but are not associated with the
characteristic infection-induced diarrhea seen in humans and can
thus not be used for investigations of this clinical manifestation
and its treatment. On the other hand, large animals such as
piglets and calves develop marked diarrhea (Tzipori et al., 1981,
1983; Argenzio et al., 1993; Gookin et al., 2008; Adell et al.,
2013; Operario et al., 2015), but require greater resources and are
less amenable to genetic and pharmacological manipulations for
mechanistic studies.
Mice are the most commonly used models for in vivo testing
of drug candidates against Cryptosporidium. Newborn mice are
susceptible to infection with C. parvum during the initial 3 weeks
after birth, but subsequently become resistant to infection.
Consequently, adult wild-type mice are generally not suitable
for drug testing, which is presumably due to eﬀective innate or
acquired immune defenses. However, adult mice with selected
immunodeﬁciencies can be readily infected with the parasite. For
example, SCID mice (Kuhls et al., 1992) and mice deﬁcient in
IFN-γ or its receptor (Theodos et al., 1997; von Oettingen et al.,
2008), major histocompatibility complex class II (Aguirre et al.,
1994), CD40 or CD40 ligand (Cosyns et al., 1998; Hayward et al.,
2001), or IL-12 p40 (Urban et al., 1996; Campbell et al., 2002)
are all susceptible to intestinal C. parvum infection and have
been used to varying degrees for drug testing. The observation
that nitazoxanide has eﬃcacy in immunocompetent patients, but
less so or not at all in immunodeﬁcient individuals suggests
that intact host immunity contributes to drug eﬀectiveness. It
follows that the nature of an immune defect that renders adult
mice susceptible to Cryptosporidium may impact the predictive
value of in vivo drug testing. However, few if any comparative
drug eﬃcacy studies have been done between diﬀerent murine
models, so it is not clear whether any particular model is more
representative of the human situation than others and thus
potentially more predictive of clinical eﬃcacy.
New Agents against Cryptosporidium
Antimicrobial drug development commonly proceeds along one
of two pathways, focused either on whole-cell activity or on
speciﬁc molecular targets. In an activity-centered approach,
compound libraries are screened for activity against the live
parasite in a suitable in vitro assay. Upon identiﬁcation
of biologically active “hits”, the respective compounds are
systematically optimized for in vitro and ultimately in vivo
activity. In a target-centered approach, the focus is on exploiting
molecular targets that are indispensable and, ideally, unique
to the parasite. Target identiﬁcation may come from genomic
analyses or genetic screens, and is followed by pharmacological
exploration of their “druggability” with suitable inhibitors.
Both approaches have advantages and shortcomings. Activity-
centered drug development can rapidly lead to strong hits and
lead compounds, but if those fail in subsequent preclinical
or clinical trials, development might run into a dead end
because the molecular target is often not known can thus
not be further exploited with alternative chemical scaﬀolds.
Target-centered drug development is conceptually compelling,
as it promises systematic exploitation of genome information
without the uncertainty of large library screens. However, targets
may not prove as physiologically critical as initially predicted,
and development of speciﬁc inhibitors with adequate activity
in vitro and in vivo may not be straightforward. Furthermore,
tools for genetic manipulation of Cryptosporidium are not
presently available, precluding genetic screens as a strategy for
identifying critical target genes in this parasite. To date, activity-
centered approaches have yielded most if not all clinically
utilized antimicrobials, while target-centered approaches remain
an intriguing but unﬁlled promise.
Both drug development strategies have been applied to
Cryptosporidium. In particular, the obligate endosymbiotic
growth phase has sparked great interest in the systematic
exploitation of this apparent “Achilles’ heel” of the parasite.
Cryptosporidium has degenerate mitosomes instead of
mitochondria and has lost the mitochondrial genome and nuclear
genes for many mitochondrial proteins, including those required
for the tricarboxylic acid cycle, oxidative phosphorylation, and
fatty acid oxidation (Abrahamsen et al., 2004; Xu et al., 2004).
Also lacking are genes for de novo biosynthesis of amino acids,
nucleotides, and sugars (Abrahamsen et al., 2004; Xu et al.,
2004). Loss of genes from multiple metabolic pathways indicates
that the parasite relies heavily on scavenging nutrients from the
host, salvage rather than de novo biosynthesis, and glycolysis
or substrate-level rather than oxidative phosphorylation for
energy production (Ryan and Hijjawi, 2015). Consequently, the
parasite must depend on these essential core metabolic pathways,
which are absent in or highly divergent from those in humans
and animals, making many of the enzymes in these pathways
potential drug targets.
Perhaps the most extensively studied metabolic pathway for
drug development is the salvage of purines for nucleic acid
synthesis. Cryptosporidium cannot synthesize purine nucleotides
de novo, but instead converts adenosine salvaged from the
host into guanine nucleotides via a pathway involving inosine
5′-monophosphate dehydrogenase (IMPDH; Umejiego et al.,
2004). This enzyme catalyzes the conversion of inosine-
5′-monophosphate into xanthosine-5′-monophosphate as the
rate-determining step in guanine nucleotide biosynthesis.
Interestingly, the parasites appear to have obtained their IMPDH
gene by lateral gene transfer from bacteria, making it structurally
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distinct from mammalian IMPDH enzymes (Striepen et al.,
2004). The exclusive reliance on this guanine salvage pathway
makes IMPDH a potential drug target. Indeed, generic inhibitors
of the enzyme have signiﬁcant anticryptosporidial activity in vitro
(Striepen et al., 2004). Subsequent studies have systematically
advanced the development of more speciﬁc inhibitors. Based
on high throughout screens, a number of structurally diverse
IMPDH inhibitors were identiﬁed (Umejiego et al., 2008), and
several of the most promising scaﬀolds were then explored for
optimal activity in vitro and in vivo. For example, a number of
derivatives of urea, benzoxazole, and benzopyrano[4,3-c]pyrazole
are active against puriﬁed IMPDH in the low to mid nM range
(Gorla et al., 2012, 2013; Sun et al., 2014), and several have
activity against C. parvum in cell culture and in a mouse infection
model in vivo (Gorla et al., 2014). As an alternative strategy to
conventional hit identiﬁcation and lead optimization of small
“drug-like” molecules, peptides have been explored as IMPDH
inhibitors. In particular, phylomer peptides, which represent
naturally stable protein segments from phylogenetically diverse
bacterial genomes with an evolutionarily optimized ability to
bind protein surfaces (Watt, 2009), have been screened for
inhibitory activity against C. parvum IMPDH (Jeﬀeries et al.,
2015). Peptides that interact with IMPDH were identiﬁed in a
yeast two hybrid screen, and then tested for parasite inhibition
in vitro. The best peptides suppressed C. parvum growth with
50% eﬃciency at 8–46 μM, but had only negligible cytotoxicity
in human cells (Jeﬀeries et al., 2015). Although the in vivo
eﬃcacy of these peptides remains to be established, the data
underline that IMPDH is a valid pharmacological target for
parasite inhibition. Taken together, the recent studies suggest
that further preclinical development of IMPDH inhibitors, using
either current scaﬀolds or perhaps yet to be discovered ones,
holds great promise for a new class of anticryptosporidial
agents.
Several other molecular targets have been explored against
Cryptosporidium. For example, the C. parvum genome encodes
three long chain fatty acyl-coenzyme A synthetases, which are
essential in the fatty acid metabolism of the parasite (Guo et al.,
2014). Their inhibition with triacsin Cwas highly eﬀective against
parasite growth in vitro and reduced oocyst production by 88%
in infected IL-12 knockout mice (Guo et al., 2014). Another
target, calcium-dependent protein kinase 1 (CDPK1), plays a
role in calcium-mediated signaling of the parasite, which is
important for regulating vital functions in Cryptosporidium and
other apicomplexan parasites (Murphy et al., 2010; Ojo et al.,
2010). Inhibition of CDPK1 with pyrazolopyrimidine derivatives
blocked enzyme activity in vitro in the low nM range and
parasite growth in epithelial cells in the low μM range (Murphy
et al., 2010). Moreover, at least one of the derivatives exhibited
signiﬁcant eﬃcacy after oral dosing in a mouse infection model
(Castellanos-Gonzalez et al., 2013b). A third group of molecular
targets are cysteine proteases, which have been associated with
excystation and host cell invasion ofC. parvum (Nesterenko et al.,
1995; Perez-Cordon et al., 2011). Selective protease inhibitors
have shown promising activity against the parasite in vitro and
in vivo (Kang et al., 2012; Ndao et al., 2013), although it remains
to be established which out of the twenty or more members of the
papain-like family of cysteine proteases are responsible for these
therapeutic eﬀects.
Beyond target-centered drug development, several activity-
centered drug screening approaches have been undertaken for
Cryptosporidium. For example, a library of 727 FDA-approved
drugs or drug-like compounds with a history of use in human
clinical trials was tested for activity on parasite growth in HCT-
8 epithelial cells (Bessoﬀ et al., 2013). Approximately twenty
compounds, representing a hit rate of ∼3%, showed signiﬁcant
activity at <10 μM, with the best compounds displaying in vitro
IC50s in the range of 0.2–5 μM (Bessoﬀ et al., 2013). Mechanistic
pursuit of one of these leads revealed that the drug target is 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase,
which is required for the de novo synthesis of isoprenoids
(Bessoﬀ et al., 2013). Importantly, the parasite lacks all known
enzymes required for the synthesis of isoprenoid precursors,
so inhibition of the critical enzyme in the host blocks parasite
growth because Cryptosporidium is dependent on the host cell
for synthesis of isoprenoid precursors (Bessoﬀ et al., 2013). This
ﬁnding nicely supports the concept mentioned above that the
obligate endosymbiosis of the parasite is a potential “Achilles’
heel” that may be exploited for drug development. It must be
noted, however, that drugs that exclusively target host processes
also have an increased risk for adverse eﬀects, so it may be
more diﬃcult for such drugs compared to conventional microbe-
targeted drugs to ﬁnd an acceptable balance between parasite
clearance and other drug eﬀects.
In another screen, an existing library from the Medicines
for Malaria Venture Open Access Malaria Box was tested
for activity against C. parvum (Bessoﬀ et al., 2014). The
library represents a collection of 400 compounds selected from
19,000 structurally unique molecules with activity against the
erythrocytic stage of Plasmodium falciparum in three large
phenotypic high-throughput screening campaigns undertaken
by large pharmaceutical companies. The screen yielded 19
compounds, representing a ∼5% hit rate, with signiﬁcant
activity against C. parvum growth in HCT-8 cells at 6.6 μM
(Bessoﬀ et al., 2014), suggesting that the relatively high hit rate
of the Plasmodium-active compounds against Cryptosporidium
may be attributed to the general similarities between the two
apicomplexan parasites. The most active compounds belonged
to three chemical series, derived from the quinolin-8-ol,
allopurinol-based, and 2,4-diaminoquinazoline, and several of
the derivatives exhibited submicromolar potency in vitro (Bessoﬀ
et al., 2014). Further studies will have to explore their in vivo
eﬃcacy.
Outlook
Taken together, recent studies clearly demonstrate that new
classes of antimicrobials against Cryptosporidium are biologically
possible and pharmacologically feasible, either by advancing
leads against already identiﬁed targets or by screening new and
larger compound libraries for activity against the parasite. In
addition, analyses of the genomes and metabolomes of diﬀerent
Cryptosporidium species and genotypes are likely to reveal more
molecular drug targets. However, as scientiﬁcally promising as
drug development against Cryptosporidium is at this time, the
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major challenge for these eﬀorts is the underlying economics
(Striepen, 2013). As a disease that aﬀects mostly developing
countries and which had up to recently been signiﬁcantly
underestimated in its clinical prevalence and importance (Lal
and Hales, 2015), cryptosporidiosis remains in the category
of Neglected Diseases with low funding priority and limited
commercial interest. If a new urgency in medical progress
against the disease can be established at national funding
agencies or philanthropic organizations, meaningful and timely
progress could be made in treating and possibly preventing
cryptosporidiosis.
Giardia
Giardiasis is a major cause of diarrheal illness worldwide
with hundreds of millions annual cases. Compared to
cryptosporidiosis, giardiasis is often associated with
more prolonged, chronic diarrhea and disease even in
immunocompetent individuals, which, particularly in children,
can lead to long-term sequelae including intellectual deﬁcits and
failure to thrive. Furthermore, treatment options are currently
broader than those for cryptosporidiosis, but resistance to
existing antimicrobial drugs is becoming a clinical problem that
has not yet been described for cryptosporidiosis.
Parasite
Giardiasis is caused by Giardia lamblia (syn. G. duodenalis or
G. intestinalis), which was ﬁrst discovered in the 1600s by van
Leeuwenhoek in his own stool. G. lamblia is a ﬂagellated, enteric
parasite that belongs to the order of diplomonads in the phylum
of metamonads, a large group of ﬂagellate amitochondriate
protozoa. The parasite has a comparatively simple life cycle
(Figure 3), which occurs in a single host (monoxenous) and
involves only two forms, the infectious cyst and the replicating
trophozoite. Cysts are spread through contaminated drinking
water or food, or person-to-person contact. G. lamblia is highly
contagious, as evidenced by experimental human infection after
oral ingestion of as few as 10 cysts (Nash et al., 1987). The low
infectious dose, combined with the resistance of cysts to many
common disinfectants (Betancourt and Rose, 2004; Erickson and
Ortega, 2006), makes G. lamblia a constant threat to the safety
of public water supplies. After passing through the stomach,
trophozoites emerge from the cysts and colonize the upper small
intestine. The sequence of exposure to an acidic environment,
followed by neutral conditions and the presence of bile is
suﬃcient to trigger excystation, as has been shown in vitro
(Boucher and Gillin, 1990).
The haploid genome of G. lamblia comprises ∼12 Mb of
DNA encoding ∼5,000 genes (Morrison et al., 2007; Franzen
et al., 2009). The parasite is polyploid throughout its life cycle.
Trophozoites have two nuclei, each carrying a diploid genome,
so the overall genome is tetraploid (4N) in the trophozoite
stage (Bernander et al., 2001). During encystation, the genome
content acquires 16N ploidy through two successive rounds
of chromosome replication without intervening cell division.
Upon excystation, the cells have four nuclei, each with a
FIGURE 3 | Life cycle of Giardia lamblia. Infection begins by oral uptake of
cysts, which excyst in stomach and small intestine to form trophozoites, the
replicating, disease-causing form of the parasite. Trophozoites are motile, and
maintain their presence in the small intestine by regulated attachment to and
detachment from the small intestinal epithelium, but they do not invade
epithelial cells. Trophozoites can also differentiate by encystation in the small
intestine into cysts, which are shed in the feces and are infectious for new
hosts.
ploidy of 4N, and divide twice to form four trophozoites
containing two diploid nuclei each (Bernander et al., 2001).
Besides the polyploidy, evidence exists for allelic sequence
heterozygosity within single parasites (Ankarklev et al., 2012),
further complicating the interpretation of genome information,
as well as the use of genetic tools for identiﬁcation of potential
new drug targets. Moreover, G. lamblia displays considerable
genetic diversity. Isolates are grouped into genetic Assemblages,
A–F, with all human pathogens belonging to groups A and B,
while the others are pathogens in dogs, birds, and other species.
Genome comparison of isolates from Assemblage A and B shows
only 77% nucleotide and 78% amino acid identity in protein-
coding regions (Franzen et al., 2009), indicating that these two
assemblages truly represent diﬀerent Giardia species, despite
the historic convention of a single species name (Jerlstrom-
Hultqvist et al., 2010). Importantly, Assemblage A and B strains
infect humans throughout the world, making it critical that new
drugs are active against divergent G. lamblia strains of both
Assemblages.
Pathogenesis and Disease
Giardia lamblia causes hundreds of millions of annual cases of
diarrheal disease in endemic and epidemic fashion worldwide
(Karanis et al., 2007; Baldursson and Karanis, 2011). In the
United States, the parasite is one of the two most common causes
of outbreaks of parasitic disease, with prevalence rates of 1–7%
depending on the population sampled (Furness et al., 2000; Barry
et al., 2013). Infections are more frequent and severe in young
children, particularly in day-care centers, and among travelers,
hikers, and military personnel in the ﬁeld (Overturf, 1994; Sharp
et al., 1995). Following cyst ingestion, symptoms occur after
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a 1–2 weeks incubation period, although only about half of
all stool-positive Giardia infections are symptomatic. Frequent
clinical manifestations of giardiasis include watery diarrhea,
epigastric pain, nausea, and vomiting. The acute phase typically
lasts 1–3 weeks, although some patients can have persistent
symptoms for months. Most infections are self-limited but
recurrences are common in endemic areas. Chronic infections
can lead to weight loss and malabsorption and may be mistaken
for inﬂammatory bowel disease or anorexia nervosa (Thomas
Iv et al., 2014). Importantly, chronic giardiasis is associated
with stunting (low height for age), wasting (low weight for
height) and cognitive impairment in children in developing
countries (Berkman et al., 2002; Nematian et al., 2008; Al-
Mekhlaﬁ et al., 2013), a ﬁnding that has been reproduced in
murine models of infection (Bartelt et al., 2013). Furthermore,
acute giardiasis may disable patients for extended periods
and can elicit protracted post-infectious syndromes, including
irritable bowel syndrome and chronic fatigue (Hanevik et al.,
2014).
After emergence from cysts, the ﬂagellated G. lamblia
trophozoites colonize the upper small intestine, although
colonization of the lower small intestine, as well as stomach
and colon can occur. Trophozoites reside and replicate in the
intestinal lumen and at the intestinal epithelial surface, but do not
invade deeper layers of the mucosa. The parasite’s ability to attach
to the mucosal surface is critical for its persistence in the host
(Lauwaet et al., 2010), yet the underlying mechanisms remain
poorly deﬁned. The ventral disk of the parasite can assume a
domed conformation that is important for robust attachment
(Woessner and Dawson, 2012), whereas ﬂagellar motility is
important for positioning and orienting trophozoites prior to
attachment, but is not directly required for attachment (House
et al., 2011). Despite its “oﬀ-shore” location outside the mucosa,
the parasite actively engages mucosal immunity, although frank
inﬂammation is typically absent in most cases (Oberhuber et al.,
1997). However, villus and brush border microvillus atrophy are
common, leading to digestive enzyme deﬁciencies (Solaymani-
Mohammadi and Singer, 2011), and chronic giardiasis can lead
to overt mucosal inﬂammation with pronounced villus loss
(Hanevik et al., 2007).
Giardiasis is self-limiting in >85% of cases in non-
endemic areas, indicating that eﬀective immune defenses exist.
Furthermore, symptoms of giardiasis are much less severe in
endemic than non-endemic regions, suggesting gradual build-
up of immunity (Faubert, 2000). Secretory IgA (Langford et al.,
2002; Davids et al., 2006), intestinal hypermotility (Andersen
et al., 2006; Li et al., 2006), and antimicrobial peptides and
nitric oxide (Eckmann et al., 2000; Tako et al., 2013) have all
been shown to have direct eﬀector activity against the parasite,
although their relative contributions to clearance of Giardiamay
be variable (Singer and Nash, 2000a; Langford et al., 2002).
Beyond direct eﬀectors, several immune cells and regulators are
known to be involved in antigiardial immune defense. Mast cells
and CD4+ T cells, but not CD8+ T cells, are required for clearing
Giardia infection (Singer and Nash, 2000a; Roxstrom-Lindquist
et al., 2006; Solaymani-Mohammadi and Singer, 2010). CD4+ T
cells may act in part by controlling antigiardial IgA responses
(Heyworth, 1989), while their functions are not related to classical
Th1 or Th2 subsets, since their signature cytokines, IFN-γ, or
IL-4, play no role in immune defense (Singer and Nash, 2000a).
In contrast, IL-6 and IL-17 are important in Giardia clearance
(Bienz et al., 2003; Zhou et al., 2003; Dreesen et al., 2014; Dann
et al., 2015). IL-6 appears to act by promoting dendritic cell
functions during infection (Kamda et al., 2012), although it has
many other activities, including activation of neutrophils and
monocytes, enhancement of follicular helper T cell responses, and
stimulation of B cell proliferation and antibody production.
A human vaccine against giardiasis is not available. A crude
veterinary vaccine (GiardiaVax), composed of total cell lysates of
a mixture of sheep, dog and human isolates, reduces symptoms
and duration of cyst output in cats and dogs (Olson et al.,
2000). Interestingly, the vaccine has also been used as an
immunotherapeutic agent in dogs with chronic giardiasis that
had failed standard drug treatment (Olson et al., 2001), raising
the intriguing possibility that a vaccine may be eﬀective post-
exposure.
Current Treatment Options
Several classes of antimicrobial drugs are available for the
treatment of giardiasis. The most commonly utilized worldwide
are members of the 5-nitroimidazole (5-NI) family such as
metronidazole and tinidazole. However, this ﬁrst line therapy
fails in up to 20% of cases and cross-resistance between diﬀerent
agents can occur (Gardner and Hill, 2001), and resistance to
all major antigiardial drugs has been reported (Ansell et al.,
2015). Alternative agents exist for treatment failures and for
special circumstances (e.g., pregnancy), but these are generally
less eﬀective than 5-NI drugs (Escobedo and Cimerman, 2007).
The oldest and most common 5-NI, metronidazole, is
typically given in three divided daily 250 mg oral doses for
5–10 days, and has a reported eﬃcacy of 80–95% (Gardner
and Hill, 2001). More recently, tinidazole, ﬁrst approved by
the FDA in 2004, has become a good alternative for giardiasis
because of its eﬃcacy (85–90%), tolerability, and convenience
(a single oral dose is recommended; Speelman, 1985). All 5-
NI drugs are prodrugs whose microbial speciﬁcity is due to the
requirement for reduction to toxic free radical intermediates
by low redox potential reactions present only in the anaerobic
target microbes (Upcroft and Upcroft, 2001). The metabolism of
G. lamblia is fermentative, and electron transport proceeds in the
absence of mitochondrial oxidative phosphorylation. However,
the parasite is microaerotolerant and can reduce molecular
oxygen and thus protect the highly oxygen-sensitive, central
metabolic enzyme, pyruvate:ferredoxin oxidoreductase (PFOR),
and iron-containing ferredoxins. PFOR decarboxylates pyruvate
and donates electrons to ferredoxin, which in turn reduces
other components in the electron transport chain and leads to
ATP generation. Reduced ferredoxin can also reduce the critical
nitro group of 5-NI prodrugs to toxic radicals which kill the
parasite. Other reduction pathways, including nitroreductases
and thioredoxin reductase, also activate 5-NI drugs in Giardia
(Pal et al., 2009; Leitsch et al., 2011; Nillius et al., 2011), although
their relative importance in reducing metronidazole and other
nitro drugs remains to be established. The radicals that result
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from nitro drug reduction form covalently bonded adducts on
microbial target molecules, leading to their inactivation. The
speciﬁc molecular targets of 5-NI drugs have not been deﬁned
in G. lamblia. In spite of the general eﬃcacy of 5-NI drugs,
treatment failures in giardiasis are common (up to 20%), clinical
resistance is proven, and in vitro resistance can be induced so
that parasites grow in clinically relevant levels of metronidazole
(Wright et al., 2003; Tejman-Yarden et al., 2011).
Nitazoxanide is a nitrothiazole with broad-spectrum activity
against intestinal parasites. Like 5-NI drugs, it is a prodrug
that must be reduced to form toxic radicals, which inactivate
various microbial target molecules including PFOR (Hoﬀman
et al., 2007). It is usually given in two daily 500 mg doses for
3 days, which is more convenient dosing than metronidazole, but
has slightly lower eﬃcacy (70–80%) than 5-NI drugs (Gardner
and Hill, 2001) and is also impacted by metronidazole resistance
(Tejman-Yarden et al., 2011). In a clinical trial involving children
with diarrheal illness, nitazoxanide reduced symptom duration
in those aﬄicted with giardiasis as well as in those without
a microbiological diagnosis (Rossignol et al., 2012), further
underlining its utility as a broad-spectrum antimicrobial agent.
Benzimidazoles, such as albendazole and mebendazole, are
generally used to treat intestinal helminth infections. Albendazole
is also eﬀective in giardiasis (Gardner and Hill, 2001; Solaymani-
Mohammadi et al., 2010), although its eﬃcacy varies markedly
(25–90%) depending on the dosing regimen. Albendazole can
be taken once daily for 5 days, making it more convenient than
three-times-a-day metronidazole, and its anti-helminth activity
makes it an attractive agent for dual use purposes (Granados
et al., 2012). However, results from a Bolivian cohort study (a
region with endemicGiardia and helminth infections) found that
treatment with mebendazole reduced hookworm infections but
paradoxically led to an increase in giardiasis (Blackwell et al.,
2013), suggesting an antagonistic relationship between the two
parasites and complicating the prospect of multi-target therapies.
Quinacrine, an old malaria drug, is an acridine derivative
with excellent eﬃcacy against giardiasis (90%). A recent report
describes the experience of a family of four with giardiasis, three
of whom failed therapy with tinidazole but were cured with
quinacrine (Requena-Mendez et al., 2014). In a randomized trial
in children with giardiasis, chloroquine was equally eﬀective
as tinidazole and superior to albendazole (Escobedo et al.,
2003). Despite its good eﬃcacy, quinacrine has potentially
severe adverse eﬀects, including a number of psychiatric and
dermatologic manifestations, and is no longer commercially
available in the United States or Canada.
Finally, paromomycin is an aminoglycoside with antigiardial
activity in vitro (Edlind, 1989) and in vivo (Geurden et al., 2006).
However, it less eﬀective among adults with metronidazole-
refractory disease than other therapies and is rarely used in
clinical practice.
Therapeutic strategies for treatment-refractory giardiasis
include longer duration and/or higher doses of the original
agent, switching to a diﬀerent class of drug, or combination
therapy. In a case series of 10 patients who failed nitroimidazole
therapy, all were cured with one of the following combinations:
metronidazole or tinidazole + paromomycin + albendazole
in three cases, metronidazole + paromomycin in two cases,
tinidazole + paromomycin in two cases, tinidazole + quinacrine
in two cases, and metronidazole + quinacrine in one case
(Morch et al., 2008). All the drugs were administered for 7 or
10 days except for tinidazole, which was given for 1–7 days.
The combinations were well tolerated and had no serious
adverse eﬀects. In a case report, a HIV patient with giardiasis
was unsuccessfully treated ﬁve times with metronidazole and
albendazole, but was cured with nitazoxanide 500 mg b.i.d
for 10 days and then 1 g b.i.d. for 15 days (Abboud et al.,
2001). Susceptibility testing showed the strain to be resistant to
metronidazole and albendazole, but susceptible to nitazoxanide
(Abboud et al., 2001). Combination therapy generally decreases
the risk of developing antimicrobial drug resistance, although it
is presently not known how this concept applies to giardiasis.
Assays for Drug Development
Giardia lamblia trophozoites can be readily grown in vitro under
axenic conditions, which greatly simpliﬁes drug testing compared
to the endosymbiont Cryptosporidium. Typical assays for Giardia
involve serial drug dilutions in multi-well plates and parasite
growth for 48 h under anaerobic conditions (Valdez et al., 2009;
Miyamoto et al., 2013) (Figure 4). Cell numbers and viability can
be assessed microscopically (Gut et al., 2011), or by determining
ATP content in the cultures (Valdez et al., 2009) (Figure 2).
A number of Assemblage A and B isolates are available, and
resistant lines against all major antigiardial drugs have been
generated in the laboratory (Upcroft et al., 1996a,b; Dunn et al.,
2010; Tejman-Yarden et al., 2011). To date, drug-resistant axenic
lines have not been generated from clinical isolates derived from
patients who failed therapy, although short-term animal studies
of such isolates have shown that resistance occurs in vivo (Lemee
et al., 2000).
Appropriate animal infection models are a key requirement
for antimicrobial drug development. A number of mammals,
including diﬀerent rodents, dogs and cats, can be experimentally
infected with G. lamblia. In cats and dogs, giardiasis has
veterinary relevance (Bouzid et al., 2015), so drug development
has veterinary objectives in these species. For drug testing studies
against human G. lamblia, the most common models are mice
and Mongolian gerbils. Adult mice are not readily infectable
with most human G. lamblia strains, with the sole exception
of the Assemblage B strain, GS/M (Byrd et al., 1994). The
strain was shown to cause diarrheal disease upon experimental
inoculation in humans (Nash et al., 1987), so it is a clinically
relevant, pathogenic strain, yet the reasons for its seemingly
unique ability to colonize adult mice remain unclear. However,
following the observation that resistance to infection could
be conferred by co-housing of animals, it was shown that
conditioning of mice with a cocktail of suitable antibiotics
(typically vancomycin + gentamicin or neomycin + ampicillin
or penicillin; none of these kill G. lamblia) in the drinking water
sensitizes mice to infection with a range of diﬀerent G. lamblia
strains of both A and B assemblages (Singer and Nash, 2000b;
Solaymani-Mohammadi and Singer, 2011). This conditioning
regimen is now commonly used, although the impact on drug
testing has not been explored. As an alternative, gerbils can be
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FIGURE 4 | In vitro drug assay for G. lamblia. Serial dilutions of test
compounds were made in 96-well plates, and trophozoites of G. lamblia WB
were added to the wells (2 × 103/well). After 48 h incubation at 37◦C under
anaerobic conditions, cell growth and viability was determined with an ATP
assay. (A) Representative phase-contrast images for controls without added
drug (left) and cells exposed to 20 μM metronidazole (right). (B) A
concentration-response curve for metronidazole. Data are mean ± SD of
triplicate wells, and are expressed relative to the G. lamblia numbers in
untreated controls. The IC50 for metronidazole was 2.1 μM in this experiment.
infected with a wide range of human G. lamblia strains without
antibiotic conditioning (Tejman-Yarden et al., 2011, 2013; Benere
et al., 2012). They have proven valuable for pathophysiologic and
immunological studies, but have not been widely used for drug
testing.
New Drugs
The discovery of antibiotics revolutionized medicine and
represents a turning point in human history. Unfortunately,
enthusiasm for these miracle drugs was soon tempered by
the emergence of resistant strains. As in bacteria, protozoa
like Giardia can develop resistance that make widely used
agents ineﬀective. While still uncommon, antibiotic resistance
(especially against 5-NI drugs) is increasing in G. lamblia
and contributes to treatment failures (Lemee et al., 2000).
Elucidating the complex resistance mechanisms is an active area
of investigation and important insights have been gained over
the last decade. Recent studies indicate that drug resistance
in G. lamblia is caused by one of several diﬀerent cellular
adaptations. Of these, the best described mechanism is the
loss of the parasite’s ability to activate nitro prodrugs to toxic
radicals by reduction, thus eﬀectively allowing the parasite to
avoid suicidal drug activation. For example, suppression of
PFOR leads to metronidazole resistance (Dan et al., 2000)
and certain strains of metronidazole-resistant G. lamblia have
reduced levels of this critical enzyme required for ferredoxin-
dependent drug activation (Leitsch et al., 2011). Other drug
activation pathways have been identiﬁed, and they can also
be impacted in resistant cells (Pal et al., 2009; Leitsch et al.,
2011; Nillius et al., 2011). Another mechanism of drug
resistance to both metronidazole and nitazoxanide is altered
expression of genes involved in stress responses, including
heat-shock proteins and expression of nitazoxanide-binding
proteins (Muller et al., 2008). Fortunately, metronidazole-
resistant giardiasis is not yet common in clinical practice,
perhaps because of the detrimental eﬀects of metronidazole
resistance on attachment and infectivity in a subset of organisms,
although others with resistance can infect normally (Tejman-
Yarden et al., 2011). Resistance to other antigiardial drugs
also exists. For example, resistance to benzimidazoles is
thought to occur through mutations in the molecular target,
β-tubulin (Aguayo-Ortiz et al., 2013). Overall, the studies
on emerging drug resistance and the underlying mechanisms
underline that the development of new antigiardial agents to
broaden the therapeutic armamentarium remains an important
challenge.
The goals of new drug development against G. lamblia and
Cryptosporidium are somewhat diﬀerent. For Cryptosporidium,
only one moderately eﬀective drug (nitazoxanide) is available,
so new classes of more eﬀective drugs are a high priority.
By comparison, for G. lamblia, several classes of drugs with
good eﬃcacy exist, but dosing regimens are suboptimal
or emerging resistance begins to threaten clinical utility.
Consequently, improvements in potency and dosing,
and the ability to overcome existing and prevent new
forms of drug resistance are priorities in antigiardial drug
development. A number of strategies have been employed
for the development of new drugs against G. lamblia, which
include, as for Cryptosporidium, both activity- and target-
centered approaches. In addition, optimization within existing
drug classes, analogous to the development of next-generation
β-lactam antibiotics, has played a much more important
role in drug development against G. lamblia compared to
Cryptosporidium.
Prime examples for the potential of optimization within
an existing drug class are the 5-NI compounds. The most
common 5-NI, metronidazole, is composed of a 5-membered
nitroimidazole core carrying simple hydroxyethyl and methyl
side chains in the 1′ and 2′ position, respectively (Figure 5).
Modiﬁcations of these side chains have been a productive
strategy for developing new and improved agents. For example,
substitution of side chains in the 1′, 2′, or 4′ positions of
the imidazole ring with larger and more complex functional
groups has led to compounds with enhanced (up to 500-
fold) antigiardial activity (Upcroft et al., 2006; Valdez et al.,
2009; Miyamoto et al., 2013) (Figure 5). Importantly, many
of the new 5-NI compounds were able to overcome existing
forms of metronidazole resistance (Miyamoto et al., 2013).
The underlying mechanisms for improved activity remain to
Frontiers in Microbiology | www.frontiersin.org 10 November 2015 | Volume 6 | Article 1208
Miyamoto and Eckmann New Drugs Against Cryptosporidium and Giardia
FIGURE 5 | Structures of 5-nitro antimicrobial drugs. The structures of
metronidazole (left) and a 2-position derivative are depicted, along with their
respective in vitro EC50 values against a representative strain of G. lamblia
(Valdez et al., 2009). The numbers along the core imidazole of metronidazole
designate the ring positions.
be determined but may relate to diﬀerential drug activation
by one or more reductases (Leitsch et al., 2011; Nillius et al.,
2011). For other metronidazole derivatives it was shown that
they were more active than the parent compound in altering
the morphology and ultrastructure of G. lamblia by aﬀecting
vesicle traﬃcking and diﬀerentiation into cysts (Busatti et al.,
2013). Similar advances have been demonstrated for the 5-
nitrothiazole, nitazoxanide, where placement of a benzene
ring between the nitro group and the thiazole ring was
used to create new benzologues (Navarrete-Vazquez et al.,
2011). The best compounds were ﬁve-times more active than
nitazoxanide and 18-times more active than metronidazole
against G. lamblia and showed minimal toxicity in mammalian
cells (Navarrete-Vazquez et al., 2011). In another series of
nitrothiazole derivatives, substitutions at 2′ position with a range
of acylamino side chains yielded compounds with >10-fold
greater activity against G. lamblia than the reference compound
nitazoxanide (Nava-Zuazo et al., 2014). Collectively, these
studies demonstrate that systematic structural modiﬁcations
of existing nitro drugs are likely to yield vastly improved
antimicrobials that can serve as “next-generation” nitro drugs
for the treatment of giardiasis and potentially other infections
with clinically important anaerobic pathogens (Miyamoto et al.,
2013).
Similar modiﬁcation strategies have been applied to
benzimidazoles, whose prototype compound, albendazole,
has been used as an alternative to 5-NI drugs against giardiasis.
A number of novel derivatives have been created, including
an alkylthiol group at the 2′ position and an ethoxy group at
the 5′ position of the benzimidazole ring, resulting in highly
potent compounds with antigiardial activity in the 10–50 nM
range (Perez-Villanueva et al., 2013). Using reverse-phase
high performance liquid chromatography and permeability
assays with cultured epithelial cells, it was observed that the
antigiardial activity of a series of benzimidazole derivatives
was inﬂuenced by their lipophilicity, hydrogen bond donors,
and molecular volume, but not by their apparent permeability
across epithelial cell monolayers (Hernandez-Covarrubias
et al., 2012). A computational analysis of the structure-activity
relationships of multiple benzimidazoles showed complex
activity landscapes for antigiardial activity, with substitution at
position 2 on the benzimidazole moiety playing an important
role in increasing potency and substitutions at positions 4–7
inﬂuencing selectivity against G. lamblia over other protozoan
parasites (Perez-Villanueva et al., 2010). These ﬁndings oﬀer
hope that quantitative models may help to identify structural
properties associated with enhanced antigiardial activity in
future drug design, at least for compounds that have well-deﬁned
molecular targets such as β-tubulin for benzimidazoles (Aguayo-
Ortiz et al., 2013). Similar structure activity analyses have been
conducted for 5-NI derivatives (Miyamoto et al., 2013), although
the current lack of understanding of the speciﬁc reductases
involved in prodrug activation or the molecular targets of
activated drugs confounds these analyses and complicates their
exploitation in drug development.
Besides compound optimization within existing drug classes,
activity-centered screens of drug libraries have also been applied
to G. lamblia. For example, a screen of 1,520 compounds
from the BIOMOL ICCB Known Bioactives 2 and NINDS
Custom Collection 2 libraries for growth-inhibitory activity
against G. lamblia yielded 48 initial hits, some of which, such
as indirubin, were not known to kill G. lamblia, although many
others had known antigiardial agents or were broad inhibitors
of cellular functions (e.g., actinomycin D; Bonilla-Santiago et al.,
2008). Such toxic compounds are not likely to be of clinical
utility. By comparison, screening of libraries of FDA-approved
drugs has the distinct advantage that preclinical safety testing
has already been done, which can accelerate the progression to
clinical trials of eﬃcacy. For instance, screening of a library of 746
compounds available for human use found that auranoﬁn, which
is employed in the treatment of rheumatoid arthritis, inhibited
the growth and survival of multiple diﬀerent G. lamblia isolates
(Tejman-Yarden et al., 2013). Importantly, auranoﬁn completely
overcame metronidazole resistance (Tejman-Yarden et al., 2013).
The action mechanism involved inhibition of thioredoxin
oxidoreductase, a critical enzyme involved in maintaining
normal protein function and combating oxidative damage in
G. lamblia and other parasites including Entamoeba histolytica
and Schistosoma mansoni (Kuntz et al., 2007; Debnath et al.,
2012; Tejman-Yarden et al., 2013). Given that its pharmacokinetic
properties and toxicology are well established (Blocka et al.,
1986), auranoﬁn may be a promising new candidate for the
treatment of drug-resistant giardiasis. In another screen, a total
of 2,816 compounds from the Library of Pharmaceutical Active
Compounds (LOPAC1280) and the NIH Chemical Genomics
Center Pharmaceutical collection library (NPC) were tested for
activity against G. lamblia (Chen et al., 2011). Detailed follow-up
studies of 28 of the most active compounds identiﬁed three new
drugs, fumagillin, carbadox, and tioxidazole, with strong activity
against metronidazole-sensitive and -resistant G. lamblia isolates
(Kulakova et al., 2014). Furthermore, fumagillin, a complex
biomolecule derived from Aspergillus fumigatus with known
antimicrobial activities against Entamoeba and microsporidia,
was eﬃcacious in a mouse giardiasis model (Kulakova et al.,
2014).
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An abbreviated form of activity-centered drug discovery is
the retesting of compounds that have shown activity in related
microbes. Screening of an NIH Chemical Genomics Center
Pharmaceutical Collection containing >2,000 compounds
identiﬁed 32 highly active compounds against Plasmodium
falciparum (Yuan et al., 2011). One of these, tetrahydrolipstatin
(orlistat), a lipase inhibitor approved for the treatment of
obesity, was then tested for growth inhibition of G. lamblia,
based on the general rationale that eﬃcient lipid metabolism is
important for a fast growing parasite such as Giardia. Orlistat
showed a potent and dose-dependent inhibition of G. lamblia
replication, with a half maximal inhibitory concentration
signiﬁcantly lower than that of metronidazole (Hahn et al., 2013).
Notably, orlistat is poorly absorbed from the intestinal tract and
remains highly active in the lumen until excreted in the stool,
raising the possibility of essentially topical therapy of giardiasis.
Disadvantages of orlistat are the potential malabsorption of
lipids and other lipophilic drugs, as well as cost issues. Another
example is miltefosine, a potent oral treatment for human
visceral leishmaniasis due to Leishmania donovani. The drug
had previously been shown to kill this parasite by inducing a
cell death process with numerous cytoplasmic, nuclear, and
membrane features of metazoan apoptosis (Paris et al., 2004).
Subsequent testing of miltefosine against G. lamblia revealed
good activity in vitro and eﬃcacy in a mouse model in vivo
(Eissa and Amer, 2012). As with orlistat, trials to ascertain the
eﬀectiveness of miltefosine in humans with giardiasis will be
needed. More broadly, repurposing of existing human drugs
can be a powerful and resource-eﬃcient strategy for rapid
progress in drug development, but the ﬁnite number of existing
compounds (with only ∼1,500 currently FDA-approved drugs)
ultimately limits this discovery path in the ongoing struggle for
new antimicrobial agents.
One way out of the closed loop of drug repurposing is the
screening of unknown chemical entities. Plants and their extracts
have historically been rich sources for new antimicrobial agents.
One of these is the naturally occurring weed Oxalis corniculata,
long used in India for treating dysentery and diarrhea. Systematic
fractionation of extracts was used to isolate a novel galacto-
glycerolipid compound with antigiardial activity comparable
to metronidazole (Manna et al., 2010). The compound had
no toxicity in human cells (Manna et al., 2010). Extracts
of sandalwood, Osyris alba, have been used by traditional
healers in Jordan to ameliorate diarrheal diseases. Phytochemical
investigation identiﬁed a new pyrrolizidine alkaloid, osyrisine,
which had signiﬁcant activity against Giardia but was non-
toxic to human cells (Al-Jaber et al., 2010). These examples
demonstrate that crude plant extracts, or perhaps in the future
other rich biological sources of structurally diverse compounds,
can be the source of new antigiardial compounds, although
their medicinal characterization, synthesis, and optimization are
likely to pose challenges not encountered with the exploration
of libraries of chemically deﬁned compounds with drug-like
properties.
The third drug development strategy, exploitation of
molecularly deﬁned targets, has been less prominent for Giardia
compared to Cryptosporidium. Nonetheless, a small number
of G. lamblia targets have been explored for druggability. The
metabolic enzyme arginine deiminase (ADI) catalyzes the ﬁrst
step in a major pathway for generating ATP in the parasite
(Knodler et al., 1998). Knock-down of ADI by RNA interference
resulted in non-viable trophozoites, indicating that ADI is
important for trophozoite survival (Li et al., 2009). Furthermore,
ADI may also serve as a virulence factor by depleting arginine
in the host, which may enable Giardia to evade the host immune
response (Eckmann et al., 2000; Banik et al., 2013). Humans
lack an analogous enzyme to ADI, making it an attractive target
for drug development. Another enzyme target is carbamate
kinase, which catalyzes the ﬁnal step in the arginine dihydrolase
pathway converting ADP and carbamoyl phosphate to ATP
and carbamate. It is essential in Giardia metabolism, but has
no equivalent in humans (Minotto et al., 1999). A luminescent
enzyme activity assay was employed in a high throughput screen
of over 4,000 compounds to identify 30 hits with activity in
the low mM range (Chen et al., 2012). Although the detected
activities are low at this point, the hits could be starting points
for the development of more potent and selective inhibitors
of carbamate kinase in G. lamblia and ultimately a novel
class of antigiardial drugs. A third attractive target enzyme in
Giardia is fructose 1,6-bisphosphate aldolase (FBPA), which
catalyzes the reversible cleavage of D-fructose-1,6-bisphosphate
to dihydroxyacetone phosphate and glyceraldehyde 3-phosphate,
a key step in the Embden–Meyerhof–Parnas glycolytic pathway
used by amitochondriate protozoa as a main source of energy
(Li et al., 2011). FBPA is critical for Giardia survival and had
unique structural and functional features that distinguish it
from human analogs (Galkin et al., 2007). Inhibitors of the
enzyme have antigiardial activity in the 100 nM range and
very low mammalian cytotoxicity (Navarrete-Vazquez et al.,
2015).
Outlook
Several treatment options currently exist for giardiasis, but
important therapeutic challenges remain. One major objective
is improvements in dosing, ideally in form of a single, highly
eﬀective oral dose, which is the ultimate goal for most if
not all tropical infection diseases as it allows diagnosis and
deﬁnitive treatment on a single clinic visit. Another objective is
the ability to overcome and prevent drug resistance, which is
not yet common for G. lamblia, but constitutes a continuous
threat that should not be taken lightly. Current studies suggest
that these objectives can be achieved within existing classes
of drugs or with new classes of drugs and molecular targets.
However, as for cryptosporidiosis, a major challenge are
the economic incentives for new drug development against
giardiasis, which is clinically important throughout the world
but is typically considered a Neglected Disease with primary
health impact in low-development countries (Escobedo et al.,
2010).
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